MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PGEN stock logo

PGEN

Precigen, Inc.

$3.94
0.01
 (0.25%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  1.184B
Shares Outstanding:  167.066M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Helen Sabzevari
Full Time Employees:  143
Address: 
20374 Seneca Meadows Parkway
Germantown
MD
20876
US
Website:  https://www.precigen.com
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/11/13 — Q3 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue6,2253,9259,684
Gross Profit106-3423,588
EBITDA-89,226-123,496-103,401
Operating Income-99,758-135,029-106,600
Net Income-95,904-126,235-250,642

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets151,043145,266155,505
Total Liabilities32,545106,753134,594
Total Stockholders Equity118,49866,730.99920,911
Total Debt7,0975,50298,290
Cash and Cash Equivalents7,57829,51730,234

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-66,930-68,173-87,831
Capital Expenditure-1,536-8,5840
Free Cash Flow-68,466-76,757-87,831
Net Income-95,904-126,235-250,642
Net Change in Cash-40,74821,6690

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)482,933.749Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)674,610.054Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)580,463Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-674,610.054Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-482,933.749Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-580,463Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)242,915.981Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)376,335.271Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)310,801.797Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)2,514,976.741Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,513,170.489Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,022,880.358Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.020Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.240Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.800Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
6.225M  ?P/S
 (TTM)
: 
123.47
?Net Income
 (TTM)
: 
-95904000  ?P/E
 (TTM)
: 
-4.97
?Enterprise Value
 (TTM)
: 
1.171B  ?EV/FCF
 (TTM)
: 
-12.94
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-83.97  ?ROIC
 (TTM)
: 
-0.92
?Net Debt
 (TTM)
: 
-22882000  ?Debt/Equity
 (TTM)
: 
0.24
?P/B
 (TTM)
: 
59.57  ?Current Ratio
 (TTM)
: 
3.09

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate PGEN Intrinsic Value

Common questions about PGEN valuation

Is Precigen, Inc. (PGEN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Precigen, Inc. (PGEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PGEN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PGEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PGEN’s P/E ratio?

You can see PGEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PGEN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PGEN a good long-term investment?

Whether PGEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

PGEN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0.25
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 1.11   Year High: 5.47
Price Avg 50: 4.02   Price Avg 200: 3.5
Volume: 5.387M   Average Volume: 4.509M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
01-04-2026 01:32
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
30-03-2026 08:30
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
26-03-2026 12:08
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
25-03-2026 18:56
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen Reports Full Year 2025 Financial Results and Business Updates
25-03-2026 16:05
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
11-03-2026 16:05
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read